The Lancet Summit:
Presymptomatic Prevention and Treatment of Neurodegenerative Diseases
27 - 29 January 2021 | QEII Centre, London
We understand you may be concerned about not being able to attend due to the Coronavirus COVID-19 situation. Rest assured that we will refund your registration fee, with no penalty, should you wish to cancel during the uncertainty of the outbreak.
The Elsevier conference team take the safety and well-being of their entire delegation and community very seriously. We will therefore be implementing a number of enhanced hygiene and cleaning measures, in collaboration with our conference venues, when our events take place. We will also of course, be following appropriate social distancing measures, to keep everyone safe throughout the conference.
This is coupled with our promise to refund your registration fee, with no penalty, should you wish to cancel during the uncertainty of the outbreak.
The biological paths that lead to Alzheimer’s disease and other neurodegenerative disorders start many years before clinical symptoms arise. In research settings, diagnostic criteria for these diseases now involve the use of biomarkers that reveal such pathophysiological changes.
Researchers are identifying and refining genetic, radiological, and CSF and blood biomarkers. At the same time, the effects on these biomarkers of therapies that could halt or delay neurodegeneration are being tested in clinical trials. These advances could ultimately enable Alzheimer’s disease and other neurodegenerative disorders to be prevented at preclinical stage.
Landmark biomarker and prevention studies, and hypothetical models of preclinical neurodegenerative diseaseshave been reported in The Lancet and The Lancet Neurology over the past decade. Reflecting our commitment to support this crucial area of neurological research, this Summit will provide a timely update on the latest advances and challenges in this area, with an emphasis on prevention.
The Summit will also provide a forum for discussion of the ethical and regulatory issues that these advances will bring about in research settings and clinical practice.
The programme will cover these topics:
- Genetics, cellular pathways, and neuronal vulnerability
- Biomarkers and early diagnosis
- Prevention through therapeutics
- Ethical and regulatory considerations
- Nick Fox, UK
- John Hardy, UK
- Karen Duff, UK
- Virginia Lee, USA
- Ammar Al-Chalabi, UK
- Henrik Zetterberg, UK
- David Klenerman, UK
- Alexandra Durr, France
- Reisa Sperling, USA
- Sarah Tabrizi, UK
- Adam Boxer, USA
- Timothy Miller, USA
- Samantha Budd, USA
- Holly Kordasiewicz, USA
- Rachelle Doody, Switzerland
- Billy Dunn, USA
- Patricia Saidon, Argentina
- Sonia Vallabh and Eric Minikel, USA
- Michael Rawlins, UK
- Elena Becker-Barroso, Editor, The Lancet Neurology, UK
- Helen Frankish, Executive Editor, The Lancet, UK
- Nick Fox, University College London, UK
- John Hardy, University College London, UK
- Jonathan Rohrer, Dementia Research Centre, UCL, London, UK
- Sarah Tabrizi, UCL Institute of Neurology, London, UK
